𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

✍ Scribed by Rodon, Jordi; Braña, Irene; Siu, Lillian L; Jonge, Maja J; Homji, Natasha; Mills, David; Tomaso, Emmanuelle; Sarr, Celine; Trandafir, Lucia; Massacesi, Cristian; Eskens, Ferry; Bendell, Johanna C


Book ID
125358933
Publisher
Springer US
Year
2014
Tongue
English
Weight
925 KB
Volume
32
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES